Safety and Efficacy of Immuncell-LC With Gemcitabine in Resectable Pancreatic Cancer

Clinical trial NCT04969731 · RECRUITING

Trial details

NCT number: NCT04969731
Sponsor: GC Cell Corporation
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Pancreatic Ductal Adenocarcinoma

Start date: 2021-09-07
Primary completion: 2026-12-01
Enrollment: 408

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.